Shopping Cart

No products in the cart.

Immunotherapy

Weight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.

Cancer-associated cachexia can inhibit immune checkpoint inhibitor (ICI) therapy efficacy. Cachexia's effect on ICI therapy has not been studied in large cohorts of cancer patients aside from lung cancer. We studied associations between real-world routinely collected clinical cachexia markers and...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreWeight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.

A fluorescent aptasensor for deoxynivalenol detection based on Nb.BbvCI-assisted targeted-responsive three-way junctions integrated DNA walking machine.

Deoxynivalenol (DON) contamination in cereals is a widespread issue with global implications, necessitating the development of efficient detection methods. Here, a fluorescent aptasensor integrating target-responsive DNA three-way junction (TWJ) and DNA walking machine was developed to detect DON. The DON-specific...
๐Ÿ—“๏ธ 2024-12-06
๐Ÿ“ฐ Publication: Food Chemistry
Read MoreA fluorescent aptasensor for deoxynivalenol detection based on Nb.BbvCI-assisted targeted-responsive three-way junctions integrated DNA walking machine.

Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).

Cancer cachexia can impact prognosis, cause resistance to anticancer treatments and affect the tolerability of treatments. This study aims to identify hepatocellular carcinoma (HCC) with cachexia by characterizing longitudinal body composition (BC) trajectories. This longitudinal, multicentre cohort study included unresectable...
๐Ÿ—“๏ธ 2024-11-27
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLongitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).

Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.

The primary objective of this study was to assess the frequency of body composition increases and their relationships to changes in body weight in two cohorts of real world, treatment-naรฏve, advanced non-small cell lung cancer (NSCLC) patients. One cohort received...
๐Ÿ—“๏ธ 2024-09-17
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreFrequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!